Notably, we also found that IL11+CD10+ iCAFs were a key component of CSC niche that drive tumor stemness in CSCs by upregulating the expression of SOX9 and OLFM4, leading to drug resistance via the AREG‐ERBB2 signaling pathway. Here, ERBB2 is linked to neoplasm.